<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Peripheral B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> representing 90% of lymphoid <z:hpo ids='HP_0002664'>neoplasms</z:hpo> are divided into low- and high-growth fraction <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Here we investigate regulation of DNA replication licensing during B-cell <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">lymphomagenesis</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Combined analysis of origin licensing factors Mcm2 and geminin with the proliferation marker Ki67 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SLL</z:e>/CLL, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> and Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> reveals for the first time the precise cell cycle state of these entities </plain></SENT>
<SENT sid="3" pm="."><plain>Given that tight Mcm2 downregulation defines the quiescent state (G0) and that both high- and low-growth fraction <z:hpo ids='HP_0002665'>lymphomas</z:hpo> express Mcm2, the data demonstrate that neoplastic lymphocytes of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SLL</z:e>/CLL and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> reside in an "in-cycle" G1 state and not in G0 as previously thought </plain></SENT>
<SENT sid="4" pm="."><plain>Absence of the S/G2/M phase marker geminin in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SLL</z:e>/CLL and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> further indicates failure of cell cycle progression in these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>In contrast, the high-growth fraction <z:hpo ids='HP_0002665'>lymphomas</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> and Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> exhibit differential expression of geminin, with the geminin/Ki67 ratio increasing for more aggressive <z:hpo ids='HP_0002664'>neoplasms</z:hpo> in keeping with a shortened G1 phase and thus representing an important discriminator for differential diagnosis </plain></SENT>
<SENT sid="6" pm="."><plain>These data provide new insights into abrogation of cell cycle control during B cell <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">lymphomagenesis</z:e> and suggest that combined analysis of origin licensing factors may contribute to improved treatment decisions and prognosis in haematopoietic <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
</text></document>